The evolution of drug discovery: From phenotypes to targets, and back

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Cumulative scientific and technological advances over the past two centuries have transformed drug discovery from a largely serendipitous process into the high tech pipelines of today. For thousands of years, medicines were sourced directly from nature, through observing the phenotypic effects of substances on humans or animals. Following the molecular biology revolution and initiation of the human genome project in the 1990s, target-based screening gained popularity and soon came to dominate the pharmaceutical industry. Two decades later, the phenotypic approach began to make a strong comeback, benefiting from the scalability and speed afforded by massive technological advances. This has ignited a debate over the relative productivities of phenotypic and target-based screening. However, as more integrative technologies become available, the focus of the discussion should shift from prioritizing the different approaches to finding strategies that can combine their complementary strengths. This review chronicles major trends and transformative events in the evolution of drug discovery, and underscores the importance of phenotypic approaches for past, and likely future, successes.

Original languageEnglish (US)
Pages (from-to)788-798
Number of pages11
JournalMedChemComm
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2016

Fingerprint

Drug Discovery
Screening
Human Genome Project
Phenotype
Molecular biology
Drug Industry
Medicine
Scalability
Molecular Biology
Animals
Pipelines
Genes
Productivity
Technology
Pharmaceutical Preparations
Industry

ASJC Scopus subject areas

  • Biochemistry
  • Pharmaceutical Science

Cite this

The evolution of drug discovery : From phenotypes to targets, and back. / Al-Ali, Hassan.

In: MedChemComm, Vol. 7, No. 5, 01.01.2016, p. 788-798.

Research output: Contribution to journalReview article

@article{d04e33fd8727416da22c0738c7b99a0b,
title = "The evolution of drug discovery: From phenotypes to targets, and back",
abstract = "Cumulative scientific and technological advances over the past two centuries have transformed drug discovery from a largely serendipitous process into the high tech pipelines of today. For thousands of years, medicines were sourced directly from nature, through observing the phenotypic effects of substances on humans or animals. Following the molecular biology revolution and initiation of the human genome project in the 1990s, target-based screening gained popularity and soon came to dominate the pharmaceutical industry. Two decades later, the phenotypic approach began to make a strong comeback, benefiting from the scalability and speed afforded by massive technological advances. This has ignited a debate over the relative productivities of phenotypic and target-based screening. However, as more integrative technologies become available, the focus of the discussion should shift from prioritizing the different approaches to finding strategies that can combine their complementary strengths. This review chronicles major trends and transformative events in the evolution of drug discovery, and underscores the importance of phenotypic approaches for past, and likely future, successes.",
author = "Hassan Al-Ali",
year = "2016",
month = "1",
day = "1",
doi = "10.1039/c6md00129g",
language = "English (US)",
volume = "7",
pages = "788--798",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "5",

}

TY - JOUR

T1 - The evolution of drug discovery

T2 - From phenotypes to targets, and back

AU - Al-Ali, Hassan

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cumulative scientific and technological advances over the past two centuries have transformed drug discovery from a largely serendipitous process into the high tech pipelines of today. For thousands of years, medicines were sourced directly from nature, through observing the phenotypic effects of substances on humans or animals. Following the molecular biology revolution and initiation of the human genome project in the 1990s, target-based screening gained popularity and soon came to dominate the pharmaceutical industry. Two decades later, the phenotypic approach began to make a strong comeback, benefiting from the scalability and speed afforded by massive technological advances. This has ignited a debate over the relative productivities of phenotypic and target-based screening. However, as more integrative technologies become available, the focus of the discussion should shift from prioritizing the different approaches to finding strategies that can combine their complementary strengths. This review chronicles major trends and transformative events in the evolution of drug discovery, and underscores the importance of phenotypic approaches for past, and likely future, successes.

AB - Cumulative scientific and technological advances over the past two centuries have transformed drug discovery from a largely serendipitous process into the high tech pipelines of today. For thousands of years, medicines were sourced directly from nature, through observing the phenotypic effects of substances on humans or animals. Following the molecular biology revolution and initiation of the human genome project in the 1990s, target-based screening gained popularity and soon came to dominate the pharmaceutical industry. Two decades later, the phenotypic approach began to make a strong comeback, benefiting from the scalability and speed afforded by massive technological advances. This has ignited a debate over the relative productivities of phenotypic and target-based screening. However, as more integrative technologies become available, the focus of the discussion should shift from prioritizing the different approaches to finding strategies that can combine their complementary strengths. This review chronicles major trends and transformative events in the evolution of drug discovery, and underscores the importance of phenotypic approaches for past, and likely future, successes.

UR - http://www.scopus.com/inward/record.url?scp=84971254649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971254649&partnerID=8YFLogxK

U2 - 10.1039/c6md00129g

DO - 10.1039/c6md00129g

M3 - Review article

AN - SCOPUS:84971254649

VL - 7

SP - 788

EP - 798

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 5

ER -